Related Experiment Video
Updated: Feb 12, 2026

Robot Assisted Distal Pancreatectomy with Celiac Axis Resection DP-CAR for Pancreatic Cancer: Surgical Planning and Technique
Published on: August 14, 2021
Perforated Small Intestinal Diffuse Large B-Cell Lymphoma Successfully Managed With Surgical Resection and Staged
Shunsuke Yamada1,2,3, Yoshikazu Ikoma1,4,3, Tomohiro Aizaki1,5
1Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
None:
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is a vincristine-free regimen recently approved for untreated diffuse large B-cell lymphoma (DLBCL). However, its safety in the early postoperative setting remains unclear. We report a case of primary intestinal DLBCL with suspected perforation managed with surgical resection followed by staged introduction of Pola-R-CHP. Rituximab was started on postoperative day 11, followed by CHP on day 15 as the first cycle of R-CHP. Pola was added from cycle 2. The patient showed an initial tumor reduction without serious gastrointestinal (GI) toxicity. This case suggests that staged introduction of Pola-R-CHP may minimize postoperative GI risk while maintaining safety.
Related Concept Videos
Esophageal Perforation-I: Introduction
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
Esophageal Perforation-II: Clinical Manifestations and Management
Clinical Manifestations:
Urinary Tract Calculi VI: Surgical Management
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Diffusion
Diffusion

